Showing 2051-2060 of 5771 results for "".
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2478309/Apellis Pharmaceuticals announced that a post hoc analysis of the phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETIN
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Facebook and EssilorLuxottica Announce Collaboration for Smart Glasseshttps://modernod.com/news/facebook-and-essilorluxottica-announce-collaboration-for-smart-glasses/2478288/Facebook and EssilorLuxottica announced a multiyear collaboration to develop the next generation of smart glasses. The announcement was made by Mark Zuckerberg during Facebook Connect, an annual conference held virtually from California. Terms of the deal were not disclosed. The par
- Recordati Rare Diseases Announces Availability of Cystadrops in the UShttps://modernod.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/Recordati Rare Diseases announced that Cystadrops (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States. Cystadrops is a new, viscous eye drop solution that depletes cystine crystal deposits in the corne
- Aerie Pharmaceuticals Announces FDA Approval of its Athlone, Ireland Facility for Production of Rhopressahttps://modernod.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rhopressa/2478282/Aerie Pharmaceuticals announced that its sterile fill production facility in Athlone, Ireland has received approval from the FDA for production of Rhopressa (netarsudil ophthalmic solution) 0.02% for commercial distribution in the United States. This approval comes following the FDA review of the
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- LumiThera and Diopsys Announce Collaboration and Enrollment of First Subject in the ELECTROLIGHT Study in Dry AMD Patientshttps://modernod.com/news/lumithera-and-diopsys-announce-collaboration-and-enrollment-of-first-subject-in-the-electrolight-study-in-dry-amd-patients/2478265/LumiThera announced it is collaborating with Diopsys, a provider of modern visual electrophysiology solutions. Diopsys’ technology helps eye care professionals accurately and objectively measure retinal and visual pathway function. The joint effort supports a prospective, pilot, huma
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first
- Ocular Therapeutix Announces Resolution of FDA Warning Letter Related to ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/Ocular Therapeutix announced it has received a letter from the FDA, dated September 2, 2020, closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant. The violation cited in Warning Letter (CMS #564663) has been addressed and Ocular is committed to sus
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.